Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Neurons on a black and red background

Neuropathy Score Reporting and Data System (NS-RADS) Validated

New reporting and data system for standardized evaluation and recording of peripheral nerve pathologies

American Roentgen Ray Society
Published:Mar 04, 2022
|1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00

LEESBURG, VA — According to an article in ARRS’ American Journal of Roentgenology (AJR), a new reporting and data system for standardized evaluation and recording of peripheral nerve pathologies—Neuropathy Score Reporting and Data System (NS-RADS)—has been created and validated in a multicenter study.

“The proposed NS-RADS classification is accurate and reliable across different reader experience levels and a spectrum of peripheral neuropathy conditions,” wrote lead researcher Avneesh Chhabra of University of Texas Southwestern in Dallas, TX. “NS-RADS can be used as a standardized guideline for reporting peripheral neuropathies and improved multidisciplinary communications.”

Chhabra and team’s retrospective study included 100 patients with nerve imaging examinations and known clinical diagnoses. Utilizing mutually agreed-upon qualitative benchmarks for classifying and grading peripheral neuropathies, different classes were established to account for the spectrum of underlying pathologies (unremarkable, injury, neoplasia, entrapment, diffuse neuropathy, not otherwise specified, and postintervention state) with subclasses to describe lesion severity or extent. Validation was performed by 11 fellowship-trained musculoskeletal radiologists across 10 institutions, and after initial multimedia training, all 100 cases were blind-presented to readers.

Offering a uniform lexicon and practical guideline for reporting neuropathic conditions on MRI, ultimately, NS-RADS accuracy for determining milder versus more severe categories per radiologist ranged from 88 percent to 97 percent for nerve lesions and from 86 percent to 94 percent for muscle abnormalities.

“On the basis of the overall promising interrater agreement shown in this study, we believe that the newly proposed NS-RADS classification will perform as well in routine practice as it did in this initial validation study,” the authors of this AJR article concluded.

- This press release was provided by the American Roentgen Ray Society